PL EN


Preferences help
enabled [disable] Abstract
Number of results
2012 | 5 | 77-85
Article title

Metody detekcji przerzutów komórek neuroblastoma do szpiku kostnego

Content
Title variants
Languages of publication
PL
Abstracts
EN
Neuroblastoma (NB), which is derived from the embryonic neural cells, is one of the most common childhood cancers (7–10%). Despite an increase in treatment intensity, the curability of patients, especially those in the high risk group, is still unsatisfactory. One of the causes of therapy failure may be the presence of cancer stem cells that survive chemotherapy and are capable of colonizing the bone marrow cavities. . A very important element in diagnosis of NB is the examination of bone marrow conducted either to confirm or exclude the presence of metastases. The currently used laboratory methods enable the detection of even a single NB cell and allow the monitoring of the minimal residual disease (MRD).
Discipline
Publisher

Year
Issue
5
Pages
77-85
Physical description
Contributors
  • Uniwersytet Jagielloński
  • Uniwersytet Jagielloński
References
  • Balwierz W., Nerwiak zarodkowy współczulny, [w:] Onkologia i hematologia dziecięca, red. A. Chybicka, K. Sawicz-Birkowska, PZWL, Warszawa 2008, s. 357–374.
  • Brodeur G. M., Neuroblastoma: Biological insights into a clinical enigma, „Nature Reviews Cancer” 2003, nr 3, s. 203–216.
  • Johnson E., Dean S. M. et al., Antibody-based immunotherapy in high-risk neuroblastoma, „Expert Reviews in Molecular Medicine” 2007, nr 9, s. 1–21.
  • Maris J. M., Hogarty M. D. et al., Neuroblastoma, „Lancet” 2007, nr 369, s. 2106–2120.
  • Bown N., Neuroblastoma tumor genetics: clinical and biological aspects, „Journal of Clinical Pathology” 2001, nr 54, s. 897–910.
  • Ishola T. A., Chung D. H., Neuroblastoma, „Surgical Oncology” 2007, nr 16, s. 149–156.
  • Maris J. M., Recent advances in neuroblastoma, „New England Journal of Medicine” 2010, nr 362, s. 2202–2211.
  • Hara J., Development of treatment strategies for advanced neuroblastoma, „International Journal of Clinical Oncology” 2012, nr 17, s. 196–203.
  • Kuroda T., Cellular kinetics of neuroblastoma and the role of surgery, „Pediatric Surgery International” 2011, nr 27, s. 913–917.
  • Ootsuka S., Asami S. et al., Useful markers for detecting minimal residual disease in cases of neuroblastoma, „Biological and Pharmaceutical Bulletin” 2008, nr 31, s. 1071– 1074.
  • Rajwanshi A., Srinivas R. et al., Malignant small round cell tumors, „Journal of Cytology” 2009, nr 26, s. 1–10
  • Ambros P. F., Mehes G. et al., Disseminated tumor cells in the bone marrow – Chances and consequences of microscopical detection methods, „Cancer Letters” 2003, nr 197, s. 29–34
  • . Beiske K., Burchill S. A. et al., Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: Recommendations by the International Neuroblastoma Risk Group Task Force, „British Journal of Cancer” 2009, nr 100, s. 1627–1637.
  • . Czaplicki D., Horwacik I. et al., New method for quantitative analysis of GD2 ganglioside in plasma of neuroblastoma patients, „Acta Biochimica Polonica” 2009, nr 56, s. 423–431.
  • Autissier P., Soulas C. et al., Evaluation of a 12-color flow cytometry panel to study lymphocyte, monocyte, and dendritic cell subsets in humans, „Cytometry Part A” 2010, nr 77, s. 410–419
  • Davidson B., Dong H. P. et al., The diagnostic and research applications of flow cytometry in cytopathology, „Diagnostic Cytopathology” 2012, nr 40, s. 525–535.
  • De Tute R. M., Flow cytometry and its use in the diagnosis and management of mature lymphoid malignancies, „Histopathology” 2011, nr 58, s. 90–105.
  • Batinić D., Dubravčić K., Flow cytometry in the diagnosis of childhood tumors, „Paediatria Croatica, Supplement” 2003, nr 47, s. 45–49.
  • . Okcu M. F., Wang R.-Y. et al., Flow cytometry and fluorescence in situ hybridization to detect residual neuroblastoma cells in bone marrow, „Pediatric Blood and Cancer” 2005, nr 45, s. 787–795.
  • Tsang K. S., Li C. K. et al., Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction, „Cancer” 2003, nr 97, s. 2887–2897.
  • Van Spriel A. B., Figdor C. G., The role of tetraspanins in the pathogenesis of infectious diseases, „Microbes and Infection” 2010, nr 12, s. 106–112.
  • Leccia F., Nardone A. et al., Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial phenotypes, „Cytometry Part A” 2012, Article in Press.
  • . Powner D., Kopp P. M. et al., Tetraspanin CD9 in cell migration, „Biochemical Society Transactions” 2011, nr 39, s. 563–567.
  • Focosi D., Bestagno M. et al., CD57+ T lymphocytes and functional immune deficiency, „Journal of Leukocyte Biology” 2010, nr 87, s. 107–116.
  • Bozzi F., Gambirasio F. et al., Detecting CD56+/NB84+/CD45- immunophenotype in the bone marrow of patients with metastatic neuroblastoma using flow cytometry, „Anticancer Research” 2006, nr 26, s. 3281–3287.
  • Viprey V. F., Corrias M. V. et al., Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: Quality assurance on behalf of SIOPEN-R-NET, „European Journal of Cancer” 2007, nr 43, s. 341–350.
  • Viprey V. F., Lastowska M. A. et al., Minimal disease monitoring by QRT-PCR: Guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials, „Journal of Pathology” 2008, nr 216, s. 245–252.
  • Viprey V. F., Burchill S. A., Gene expression profiling for discovery of novel markers of minimal disease, „Clinical Cancer Research” 2009, nr 15, s. 6742.
  • Lambooy L. H. J., Gidding C. E. M. et al., Real-time analysis of tyrosine hydroxylase gene expression: A sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma, „Clinical Cancer Research” 2003, nr 9, s. 812–819.
  • Gaultier C., Trang H., et al., Pediatric disorders with autonomic dysfunction: What role for PHOX2B?, „Pediatric Research” 2005, nr 58, s. 1–6.
  • . Stutterheim J., Gerritsen A. et al., Phox2B is a novel and specific marker for minimal residual disease testing in neuroblastoma, „Journal of Clinical Oncology” 2008, nr 26, s. 5443–5449.
  • Träger C., Vernby Å. et al., mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis, „International Journal of Cancer” 2008, nr 123, s. 2849–2855
  • . Bozzi F., Luksch R. et al., Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: Utility as a tumor marker for neuroblastoma, „Diagnostic Molecular Pathology” 2004, nr 13, s. 135–143.
  • Oltra S., Martinez F. et al., The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma, „Diagnostic Molecular Pathology” 2005, nr 14, s. 53–57.
  • . Modak S., Cheung N.-K. V., Disialoganglioside directed immunotherapy of neuroblastom, „Cancer Investigation” 2007, nr 25, s. 67–77.
  • Kågedal B., Detecting minimal residual disease in neuroblastoma: Still a ways to go, „Clinical Chemistry” 2009, nr 55, s. 1268–1270.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-0375319b-c801-4a24-bc36-242e606c6322
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.